Versant Ventures
Peter Emtage, Ph.D., is an accomplished professional in the biotechnology sector, currently serving as the Chief Executive Officer at Santa Ana Bio, Inc. since June 2021, while also holding a position as Venture Partner at Versant Ventures since October 2020. Prior to these roles, Peter Emtage was the Global Head of Cell Therapy Research at Kite Pharma from February 2018 to October 2020. Additionally, Peter Emtage contributed as the Chief Scientific Officer at Cell Design Labs from March 2016 to February 2018, a company known for developing innovative cell-based therapies aimed at treating cancer and other severe diseases by harnessing the immune system's capabilities.
Versant Ventures
1 followers
Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $2.4 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and clinical expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 70 Versant companies have achieved successful acquisitions or IPOs.